Myocardial Tissue Reconstruction Using Injectable Scaffolds

Abstract

Myocardial tissue reconstruction represents an evolving frontier in cardiovascular medicine, particularly following ischemic injury such as myocardial infarction (MI). Injectable scaffolds have emerged as a promising approach to facilitate myocardial repair, leveraging advances in biomaterials, tissue engineering, and regenerative medicine. This review synthesizes the current scientific and clinical evidence regarding injectable scaffolds for myocardial tissue reconstruction, encompassing their mechanisms, clinical indications, outcomes, risks, and future prospects, with a focus on translating recent advances into practical, guideline-aligned strategies for physicians and healthcare professionals.

Introduction

Ischemic heart disease, especially MI, is a leading cause of morbidity and mortality globally. Post-infarction, the heart undergoes a cascade of maladaptive remodeling, often culminating in heart failure. Traditional therapies primarily aim to limit infarct size and manage symptoms, but do not directly address the loss of viable myocardium. Myocardial tissue engineering, specifically using injectable scaffolds, has emerged as a novel strategy to restore cardiac structure and function by providing a supportive microenvironment for cell survival, differentiation, and tissue regeneration. This review critically appraises the underlying principles, clinical application, and outcomes of injectable scaffolds for myocardial reconstruction.

Epidemiology / Disease Burden

Cardiovascular diseases (CVDs) remain the foremost cause of death worldwide, accounting for approximately 17.9 million deaths annually. MI, a predominant manifestation of CVD, leads to substantial loss of cardiomyocytes, irreversible scar formation, and progressive ventricular dysfunction. The burden of post-MI heart failure is rising, with an estimated 26 million people affected globally. Despite advances in reperfusion and pharmacological therapies, the inability of adult myocardium to regenerate effectively underscores the unmet need for regenerative strategies such as injectable scaffolds.

Pathophysiology

The pathological hallmark of MI is acute ischemic injury resulting in extensive cardiomyocyte death. The subsequent inflammatory response promotes scar tissue deposition, replacing lost myocardium with non-contractile fibrotic tissue and impairing cardiac function. Remodeling processes, including dilatation and hypertrophy, further exacerbate dysfunction. Injectable scaffolds are designed to interrupt this maladaptive sequence by providing a biocompatible, bioactive matrix that supports endogenous repair, cell homing, angiogenesis, and potentially the integration of exogenous therapeutic cells.

Risk Factors

Risk factors for myocardial damage necessitating reconstruction include traditional cardiovascular risk determinants: hypertension, dyslipidemia, diabetes mellitus, smoking, obesity, and a positive family history of premature CAD. Patients with large infarcts, poor collateral circulation, delayed reperfusion, or recurrent ischemic events are at heightened risk for extensive myocardial loss and adverse remodeling, rendering them prime candidates for regenerative interventions such as scaffold-based therapies.

Clinical Features

Patients with significant myocardial injury may present with persistent angina, dyspnea, reduced exercise tolerance, and signs of heart failure (e.g., pulmonary congestion, peripheral edema). On examination, findings such as S3 gallop, displaced apex beat, and elevated jugular venous pressure may be evident. These clinical features highlight the functional deficit resulting from loss of contractile tissue and reinforce the necessity for innovative reconstructive approaches.

Diagnosis

Diagnosis of myocardial damage suitable for reconstruction involves multimodal assessment. Echocardiography remains the cornerstone, providing quantification of ventricular function, wall motion abnormalities, and scar extent. Cardiac MRI offers superior tissue characterization, delineating viable myocardium from non-viable scar. Advanced imaging modalities, including PET and SPECT, allow for assessment of myocardial perfusion and metabolic activity. Biomarkers such as troponin, NT-proBNP, and high-sensitivity CRP may aid in risk stratification and monitoring.

Treatment & Management

Standard post-MI management comprises antiplatelet agents, beta-blockers, ACE inhibitors or ARBs, statins, and lifestyle modification. When significant myocardial loss persists despite optimal medical therapy, regenerative strategies are considered. Injectable scaffolds, typically administered via percutaneous or minimally invasive surgical routes, serve as supportive matrices that can be acellular (e.g., natural polymers such as collagen, fibrin, hyaluronic acid) or cellular, incorporating stem/progenitor cells. These scaffolds are designed to be biocompatible, minimally immunogenic, and conducive to host tissue integration and vascularization.

Recent Advances / Emerging Therapies

Recent years have witnessed major advances in scaffold design, biofabrication, and delivery. Innovations include the use of decellularized extracellular matrix (ECM) hydrogels, which mimic native myocardial architecture and provide bioactive cues for cell survival and differentiation. Synthetic polymers (e.g., PEG, PLGA) are being engineered for controlled degradation and tailored mechanical properties. Emerging strategies involve the incorporation of growth factors, extracellular vesicles, and gene-editing tools to enhance regenerative efficacy. Preclinical studies demonstrate improved myocardial function, increased angiogenesis, and reduced scar formation with injectable scaffolds. Early-phase clinical trials, such as those evaluating VentriGel and alginate-based scaffolds, report favorable safety profiles and suggest potential improvements in left ventricular ejection fraction and quality of life.

Guideline Recommendations

While injectable scaffolds are not yet part of routine clinical guidelines, major societies such as the American Heart Association and European Society of Cardiology recognize the promise of regenerative therapies and support their evaluation in rigorously designed clinical trials. Current recommendations emphasize patient selection, multidisciplinary team involvement, and participation in approved research protocols. Ongoing studies are expected to inform future integration of injectable scaffold therapies into evidence-based guidelines as more robust efficacy and long-term safety data become available.

Conclusion

Injectable scaffolds for myocardial tissue reconstruction represent a paradigm shift in the management of post-infarction cardiac injury. By providing structural support and a bioactive environment conducive to repair, these scaffolds hold the potential to restore myocardial integrity and function beyond the capabilities of conventional therapies. Continued advances in scaffold engineering, delivery methods, and adjunctive biologics are likely to refine their efficacy and safety. As clinical evidence accumulates, carefully selected patients may benefit from these transformative therapies, heralding a new era in cardiac regenerative medicine.